Mexico Cell And Gene Therapy Clinical Trials Market Size & Outlook

The cell and gene therapy clinical trials market in Mexico is expected to reach a projected revenue of US$ 425.3 million by 2030. A compound annual growth rate of 14.3% is expected of Mexico cell and gene therapy clinical trials market from 2024 to 2030.

Revenue, 2023 (US$M)
$167.4
Forecast, 2030 (US$M)
$425.3
CAGR, 2024 - 2030
14.2%
Report Coverage
Mexico

Mexico cell and gene therapy clinical trials market, 2018-2030 (US$M)

Mexico

Mexico cell and gene therapy clinical trials market highlights

  • The Mexico cell and gene therapy clinical trials market generated a revenue of USD 167.4 million in 2023 and is expected to reach USD 425.3 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 14.3% from 2024 to 2030.
  • In terms of segment, phase ii was the largest revenue generating phase in 2023.
  • Phase III is the most lucrative phase segment registering the fastest growth during the forecast period.


Cell and gene therapy clinical trials market data book summary

Market revenue in 2023USD 167.4 million
Market revenue in 2030USD 425.3 million
Growth rate14.3% (CAGR from 2023 to 2030)
Largest segmentPhase ii
Fastest growing segmentPhase III
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideIQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech


Other key industry trends

  • In terms of revenue, Mexico accounted for 1.8% of the global cell and gene therapy clinical trials market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2030.
  • Brazil is the fastest growing regional market in Latin America and is projected to reach USD 643.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy Clinical Trials Market Companies

Name Profile # Employees HQ Website

Mexico cell and gene therapy clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.


Phase ii was the largest segment with a revenue share of 49.88% in 2023. Horizon Databook has segmented the Mexico cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


Mexico is an attractive destination for outsourcing the cell and gene therapy clinical trials as cost plays a major factor. Moreover, the proximity to the U.S. and the availability of investigators in urban areas also help in cost-cutting. As the population here cannot afford treatment of chronic diseases, they usually prefer participating in such trials. Hence, availability of diverse patient pool is one of the drivers.

The establishment of regulatory entity, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), and shortening the set up time for cell and gene therapy clinical trials to two months has also attracted many clients. In addition to all this, there is a huge investment for infrastructure development to provide better facilities.

Mexico’s largest hospital chain has invested around USD 700 million to build 15 new hospitals to encourage cell and gene therapy clinical trials and medical tourism. Mexico is also one of the preferred countries in Latin America due to cost saving and speed with which the trials are performed. The increasing number of trials outsourced to this country has also brought about many regulatory changes favoring growth.

Reasons to subscribe to Mexico cell and gene therapy clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Mexico cell and gene therapy clinical trials market databook

  • Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Mexico cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Mexico cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)

Mexico Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

Mexico cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more